Actinogen logo

Actinogen Medical

AU: ACW

AU$50.4m market cap

AU$0.05 last close

Actinogen Medical is an ASX-listed Australian biotech developing lead asset Xanamem, a specific 11beta-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurological and metabolic diseases.

Investment summary

Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurodegenerative and metabolic diseases.

In this video, the company’s chief executive officer Bill Ketelbey provides an update on recent developments, R&D progress and expected newsflow.

Y/E Jun
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2018A 3.3 (6.0) (5.9) (0.8) N/A N/A
2019A 5.1 (9.5) (9.4) (0.9) N/A N/A
2020E 3.0 (7.5) (7.5) (0.7) N/A N/A
2021E 3.0 (12.7) (12.7) (1.1) N/A N/A
Industry outlook

The unmet need in Alzheimer’s disease is vast and the size of the market has attracted interest from almost every player in CNS drug R&D over the past 30 years with very limited success so far. With so many late-stage failures, we believe that ‘non-mainstream’ technologies, such as Xanamem, may attract renewed interest from potential partners.

Last updated on 06/12/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (A$m) 5
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 28.6 462.5 (10.0)
Relative* 27.8 457.5 (24.2)
52-week high/low A$0.1/A$0.0
*% relative to local index
Key management
Bill Ketelbey CEO & Managing Director